Minnesota Glomerular Disease Program

Minnesota Glomerular

Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller

Mission

To provide patients with glomerular disease with expert, individualized care and access to clinical trials.

Covered Diseases

  • Any glomerular disease, including (but not limited to):
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Membranous nephropathy
    • Minimal change disease 
    • IgA nephropathy
    • Immune complex mediated diseases
    • C3 Glomerulopathy
    • Fibrillary Glomerular Disease
    • Cryoglobulinemia
    • Anti-Glomerular Basement Membrane (anti-GBM) Disease
    • Alport Syndrome
    • Thin basement membrane disease
    • Vasculitis
    • Lupus Nephritis
  • For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage

Goals

  • Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with glomerular disease.

Our Team

Physicians

Clinical & Translational Research Team

Ongoing Clinical Trials

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Phase 2a Trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Principal Investigator
Patrick Nachman, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

IGA NEPHROPATHY

Phase 3 Trial

A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)

Principal Investigator
Surabhi Thakar, MD

Co-Investigator
Katti Woerner, MD

Study Coordinators

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL


Phase 3 Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Principal Investigator
Patrick H. Nachman, MD

Study Coordinators

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

MEMBRANOUS NEPHROPATHY

Phase 2 Trial

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

Principal Investigator

Patrick H. Nachman, MD

Study Coordinators

Mary McDonald, RN, CCRP
mcdo0664@umn.edu

Joy Bolea, RN, MS
jbolea@umn.edu

CLINICAL TRIAL